Compare Stocks: MREO, MDWD, PLX, and DTIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$7.00 +1.6%	$7.35	$3.53 ▼ $9.62	$177.78M	1.25	457,725 shs	235,491 shs
MDWD MediWound	$14.10 -1.8%	$14.53	$13.54 ▼ $20.30	$184.43M	0.14	71,356 shs	68,129 shs
MREO Mereo BioPharma Group	$0.32 +2.8%	$0.31	$0.20 ▼ $2.37	$48.92M	0.35	937,718 shs	772,563 shs
PLX Protalix BioTherapeutics	$2.27	$2.21	$1.41 ▼ $3.19	$182.90M	N/A	945,750 shs	259,869 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	+1.60%	-4.50%	-10.94%	-2.10%	+45.83%
MDWD MediWound	-1.78%	-1.23%	-4.12%	-14.58%	-27.08%
MREO Mereo BioPharma Group	+2.77%	+8.25%	-0.85%	+17.36%	-81.90%
PLX Protalix BioTherapeutics	0.00%	-4.22%	-2.58%	+5.58%	+52.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$7.00 +1.6%	$7.35	$3.53 ▼ $9.62	$177.78M	1.25	457,725 shs	235,491 shs
MDWD MediWound	$14.10 -1.8%	$14.53	$13.54 ▼ $20.30	$184.43M	0.14	71,356 shs	68,129 shs
MREO Mereo BioPharma Group	$0.32 +2.8%	$0.31	$0.20 ▼ $2.37	$48.92M	0.35	937,718 shs	772,563 shs
PLX Protalix BioTherapeutics	$2.27	$2.21	$1.41 ▼ $3.19	$182.90M	N/A	945,750 shs	259,869 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	+1.60%	-4.50%	-10.94%	-2.10%	+45.83%
MDWD MediWound	-1.78%	-1.23%	-4.12%	-14.58%	-27.08%
MREO Mereo BioPharma Group	+2.77%	+8.25%	-0.85%	+17.36%	-81.90%
PLX Protalix BioTherapeutics	0.00%	-4.22%	-2.58%	+5.58%	+52.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	360.71% Upside
MDWD MediWound	2.25	Hold	$34.00	141.22% Upside
MREO Mereo BioPharma Group	2.25	Hold	$3.25	931.75% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	428.63% Upside

Current Analyst Ratings Breakdown

Latest MREO, MDWD, PLX, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	MDWD MediWound	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/9/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/2/2026	MREO Mereo BioPharma Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/10/2026	MREO Mereo BioPharma Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
6/9/2026	DTIL Precision BioSciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/28/2026	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
5/27/2026	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $32.00
5/27/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
5/12/2026	MREO Mereo BioPharma Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/12/2026	MREO Mereo BioPharma Group	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1.00
5/8/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$45.07M	4.01	N/A	N/A	$4.03 per share	1.74
MDWD MediWound	$16.96M	10.68	N/A	N/A	$3.40 per share	4.15
MREO Mereo BioPharma Group	$500K	100.56	N/A	N/A	$0.26 per share	1.21
PLX Protalix BioTherapeutics	$76.38M	2.39	$0.13 per share	17.80	$0.47 per share	4.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	-$45.72M	-$3.67	N/A	N/A	N/A	-96.73%	-85.37%	-37.34%	8/6/2026 (Estimated)
MDWD MediWound	-$23.88M	-$2.26	N/A	N/A	N/A	-180.30%	-67.22%	-31.87%	8/13/2026 (Estimated)
MREO Mereo BioPharma Group	-$41.88M	-$0.05	N/A	N/A	N/A	N/A	-81.28%	-70.45%	8/11/2026 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.18	N/A	7.32	N/A	-21.03%	-30.89%	-11.74%	N/A

Latest MREO, MDWD, PLX, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MDWD MediWound	-$0.76	N/A	N/A	N/A	$2.59 million	N/A
8/11/2026	Q2 2026	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	$3.50 million	N/A
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.71	N/A	N/A	N/A	$1.40 million	N/A
5/27/2026	Q1 2026	MDWD MediWound	-$0.65	-$0.23	+$0.42	-$0.23	$3.37 million	$1.48 million
5/12/2026	Q1 2026	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.05	$11.67 million	N/A
5/5/2026	Q1 2026	DTIL Precision BioSciences	-$0.6550	-$0.75	-$0.0950	-$0.75	$4.05 million	$10.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.29	14.02	14.02
MDWD MediWound	N/A	2.41	2.19
MREO Mereo BioPharma Group	N/A	6.48	6.48
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
MDWD MediWound	46.83%
MREO Mereo BioPharma Group	62.83%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	2.70%
MDWD MediWound	9.20%
MREO Mereo BioPharma Group	6.50%
PLX Protalix BioTherapeutics	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	25.80 million	25.11 million	No Data
MDWD MediWound	80	12.85 million	11.67 million	Optionable
MREO Mereo BioPharma Group	40	159.62 million	149.24 million	Optionable
PLX Protalix BioTherapeutics	200	80.57 million	69.00 million	Optionable

MREO, MDWD, PLX, and DTIL Headlines

Recent News About These Companies

Protalix BioTherapeutics (NYSE:PLX) Trading Down 2.6% - Here's Why

July 30 at 3:02 AM | americanbankingnews.com

Protalix BioTherapeutics (NYSE:PLX) Shares Down 2.6% - Here's Why

July 30 at 2:59 AM | marketbeat.com

Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary

May 15, 2026 | finance.yahoo.com

PLX: Chiesi Milestone Received

May 14, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript

May 14, 2026 | insidermonkey.com

Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call

May 14, 2026 | uk.finance.yahoo.com

Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...

May 14, 2026 | finance.yahoo.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results

May 13, 2026 | prnewswire.com

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026

May 6, 2026 | prnewswire.com

Protalix: Elfabrio Struggles Against Oral Competition

April 15, 2026 | seekingalpha.com

Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance

March 24, 2026 | seekingalpha.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

March 18, 2026 | finanznachrichten.de

Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115

March 18, 2026 | seekingalpha.com

Protalix BioTherapeutics advances Fabry disease and gout programs during 2025

March 18, 2026 | proactiveinvestors.com

Protalix: Q4 Earnings Snapshot

March 18, 2026 | finance.yahoo.com

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

March 18, 2026 | finance.yahoo.com

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen

March 9, 2026 | proactiveinvestors.com

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase ...

March 9, 2026 | tmcnet.com

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

March 9, 2026 | globenewswire.com

Protalix BioTherapeutics (PLX) price target decreased by 12.00% to 11.22

February 4, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MREO, MDWD, PLX, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

$7.00 +0.11 (+1.60%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$7.10 +0.11 (+1.50%)

As of 07:37 AM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

MediWound NASDAQ:MDWD

$14.10 -0.26 (-1.78%)

Closing price 07/30/2026 03:59 PM Eastern

Extended Trading

$14.10 0.00 (0.00%)

As of 07:44 AM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Mereo BioPharma Group NASDAQ:MREO

$0.32 +0.01 (+2.77%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$0.31 0.00 (-1.27%)

As of 07:32 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Protalix BioTherapeutics NYSE:PLX

$2.27 0.00 (0.00%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$2.28 +0.02 (+0.66%)

As of 07/30/2026 07:41 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MREO, MDWD, PLX, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MREO, MDWD, PLX, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MREO, MDWD, PLX, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MREO, MDWD, PLX, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

MediWound NASDAQ:MDWD

Mereo BioPharma Group NASDAQ:MREO

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MREO, MDWD, PLX, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MREO, MDWD, PLX, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MREO, MDWD, PLX, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MREO, MDWD, PLX, and DTIL Company Descriptions

Precision BioSciences NASDAQ:DTIL

MediWound NASDAQ:MDWD

Mereo BioPharma Group NASDAQ:MREO

Protalix BioTherapeutics NYSE:PLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools